Diagnosis of Polycythemia Vera Without JAK2 V617F Mutation
Polycythemia vera can be diagnosed in JAK2 V617F-negative patients by testing for JAK2 exon 12 mutations and meeting the first major criterion (elevated hemoglobin/hematocrit) plus two of three minor criteria: bone marrow biopsy showing panmyelosis, subnormal serum erythropoietin, or endogenous erythroid colony formation. 1
Diagnostic Algorithm for JAK2 V617F-Negative Cases
Step 1: Confirm Elevated Red Cell Parameters
First, verify that hemoglobin meets diagnostic thresholds:
- Men: ≥18.5 g/dL
- Women: ≥16.5 g/dL
- Alternative: Documented sustained increase of ≥2 g/dL from baseline that cannot be attributed to iron deficiency correction 1
Step 2: Test for JAK2 Exon 12 Mutations
The WHO criteria explicitly recognize that "functionally similar mutations such as JAK2 exon 12 mutation" can substitute for JAK2 V617F 1. These exon 12 mutations are found in a small proportion of PV patients who lack the V617F mutation 1.
Step 3: Apply Alternative Diagnostic Pathway
When both JAK2 V617F and exon 12 mutations are absent, diagnosis requires:
The first major criterion (elevated hemoglobin) PLUS at least TWO of these three minor criteria:
Bone marrow biopsy showing hypercellularity for age with trilineage growth (panmyelosis) with prominent erythroid, granulocytic, and megakaryocytic proliferation 1
Serum erythropoietin level below the reference range for normal 1
Endogenous erythroid colony formation in vitro 1
Critical Nuances
Why Two Minor Criteria Are Required
The WHO guidelines deliberately require two instead of one minor criterion when JAK2 mutations are absent to "reinforce the accuracy associated with each test and increase the comfort level to make the specific diagnosis in the context of a negative molecular test result" 2. This higher bar minimizes false-positive diagnoses.
The Reality of JAK2-Negative PV
While JAK2 V617F is present in more than 90% of PV patients 1, the absence of detectable JAK2 mutations does not exclude PV 1. The guidelines acknowledge that some cases may be "negative for a known JAK2 mutation or associated with a mutation burden that is too low to be detected" 2.
Exclusion of Other Causes Remains Essential
Before diagnosing PV, you must exclude:
- Secondary erythrocytosis (hypoxia, high oxygen-affinity hemoglobin, EPO-secreting tumors, renal artery stenosis)
- BCR-ABL1-positive chronic myelogenous leukemia
- Other myeloid neoplasms
- Relative polycythemia (decreased plasma volume) 3, 4
Common Pitfalls to Avoid
Iron deficiency masking: Hemoglobin levels may be artificially lowered by concurrent iron deficiency. For research/clinical trial purposes, formal PV diagnosis requires demonstrating WHO criteria are met after iron replacement. However, in routine practice, you can make a working diagnosis despite iron deficiency if other criteria are compelling 2.
Incomplete mutation screening: Failure to test for JAK2 exon 12 mutations will miss a subset of true PV cases. The guidelines explicitly state that testing should include exons 12-15, not just V617F 4.
Premature labeling as "idiopathic erythrocytosis": This diagnosis of exclusion is increasingly recognized to harbor underlying genetic mutations/polymorphisms that current testing may not detect 3, 4, 5. Ensure thorough evaluation before accepting this label.
Practical Considerations
The 2008 WHO revision was designed so that meeting both major criteria captures more than 97% of PV cases 2. The alternative pathway (first major criterion plus two minor criteria) specifically targets the remaining 3% who are JAK2-negative or have undetectable mutation burdens.
Bone marrow histology is particularly valuable in JAK2-negative cases, as the characteristic panmyelosis pattern with trilineage proliferation helps distinguish PV from secondary causes of erythrocytosis 1.